Globus Med Inc Stock Price, News & Analysis

Globus Medical (NYSE: GMED) reported strong financial results for Q4 and full year 2024. Q4 worldwide net sales reached $657.3 million, up 6.6% year-over-year, with GAAP net income of $26.5 million and EPS of $0.19. Non-GAAP diluted EPS was $0.84, and adjusted EBITDA was $196.9 million.

Full year 2024 sales totaled $2,519.4 million, a 60.6% increase, with GAAP net income of $103.0 million and EPS of $0.75. Non-GAAP diluted EPS was $3.04, and adjusted EBITDA reached $735.0 million. The company generated operating cash flow of $520.6 million and non-GAAP free cash flow of $405.2 million.

For 2025, GMED projects standalone revenue of $2.66-2.69 billion with non-GAAP EPS of $3.40-3.50. Post-Nevro acquisition, expected in late Q2 2025, guidance increases to $2.80-2.90 billion in sales with non-GAAP EPS of $3.10-3.40.

Globus Medical (NYSE: GMED) has announced the acquisition of Nevro Corp. (NYSE: NVRO) in an all-cash transaction valued at approximately $250 million. Under the agreement, Globus Medical will acquire all Nevro shares for $5.85 per share, representing a 27% premium to the 90-day VWAP.

The transaction, expected to close in late Q2 2025, aims to expand Globus Medical's presence in neuromodulation and pain management technologies. The company anticipates 2025 net sales of $2.80-2.90 billion post-acquisition, with the deal expected to be earnings accretive in the second year of operation.

For 2024, Globus Medical reported preliminary net sales of $2.52 billion, a 60.6% increase year-over-year, while Nevro's preliminary worldwide revenue was $408-409 million. The acquisition has received unanimous approval from both companies' boards of directors and is subject to Nevro shareholder and regulatory approvals.

Globus Medical (NYSE:GMED) has scheduled its fourth quarter and full-year 2024 financial results announcement for Thursday, February 20, 2025, after market close. The company will host a conference call with the investment community at 4:30 p.m. Eastern Time on the same day.

Investors can access the conference call through a live webcast on the company's investor relations website. For telephone participation, advance registration is required through a provided link, after which participants will receive dial-in details and unique access credentials. An audio archive of the call will be made available on the company's investor website following the event.

Globus Medical (NYSE: GMED) reported preliminary Q4 2024 sales of $657.0 million, up 6.6% year-over-year, and full-year 2024 sales of $2.52 billion, representing a 60.6% increase from 2023. The company, following its NuVasive merger, achieved strong sales growth, record new product launches, and highest Enabling Technology placements while accelerating merger synergies.

Looking ahead, GMED provided 2025 guidance with revenue projected between $2.66 billion to $2.69 billion and non-GAAP EPS guidance of $3.40 to $3.50. The company plans to announce detailed Q4 and full-year 2024 results on February 20, 2025.

Globus Medical (NYSE: GMED) has launched ExcelsiusHub™, a new navigation system for spine surgery. The system enhances freehand navigation by providing real-time visualization of instrument placement, reducing reliance on X-ray imaging. Key features include real-time patient array monitoring, tissue-sparing drills, and registration flexibility.

The system offers three distinct workflows: Automatic registration with Excelsius3D™, CT to fluoroscopy merging, and intraoperative 2D navigation. ExcelsiusHub™ is designed for both hospital and ASC settings, supporting procedures from minimally invasive to complex spinal deformity surgeries.

Globus Medical (NYSE: GMED) reported strong Q3 2024 financial results with worldwide net sales of $625.7 million, up 63.1% year-over-year. GAAP net income reached $51.8 million with diluted EPS of $0.38, while non-GAAP diluted EPS was $0.83. U.S. net sales increased by 60.3%, and international sales grew 74.8%. The company generated $203.7 million in operating cash flow and raised its full-year 2024 guidance to revenue between $2.49-$2.50 billion, with non-GAAP EPS of $2.90-$3.00. Growth was primarily driven by the NuVasive addition and increased sales in spine products and enabling technology.

Globus Medical (NYSE: GMED) will participate in the 40th Annual Meeting of the Orthopedic Trauma Association (OTA) in Montréal, Canada, from October 23-26, 2024. The company will showcase its orthopedic trauma product portfolio at booth #361, featuring recent additions such as TENSOR™ Suture Button, ANTHEM™ II Distal Radius Volar Plates, AUTOBAHN™ Trochanteric Nail PRO Instruments, and CAPTIVATE™ SOLA Headless Screws.

Globus will also present the PRECICE™ Ankle Salvage System, designed to compress the tibia-talar-calcaneus joint and offer limb lengthening options. The company will host a workshop on internal limb reconstruction for complex cases on October 24. This marks the second year Globus Medical is presenting PRECICE™ as part of its broader orthopedic trauma portfolio, which includes FDA-cleared technologies for limb lengthening and bone transport in long bones.

Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, has announced it will release its financial results for the third quarter ended September 30, 2024, after the market close on Tuesday, November 5, 2024. The company will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time on the same day.

Investors can access the conference call via webcast on the Investors page of Globus Medical's website. For telephone participation, registration is required in advance. Upon registration, participants will receive a confirmation email with dial-in details. An audio archive of the call will be available on the company's website after the event.

Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, has announced the expansion of its orthopedic trauma product portfolio in 2024. The company has introduced several new system extensions and received FDA 510(k) clearance for its first suture-based product, the TENSOR™ Suture Button System. New launches include ANTHEM™ II Distal Radius Volar Plates, AUTOBAHN™ Trochanteric Nail PRO Instruments, and CAPTIVATE™ SOLA Headless Screws.

Surgeons across the U.S. have been implementing these new implants with positive feedback. Dr. Asif Ilyas from Thomas Jefferson University Hospital praised the ANTHEM™ II Volar plates for their contour and customization options. The company's orthopedic trauma business is experiencing rapid growth, with these new technologies and the integration of PRECICE™ magnetically actuated limb-lengthening nail technologies expanding their capacity to service diverse patient needs.